Adaptimmune Therapeutics Statistics
Share Statistics
Adaptimmune Therapeutics has 257.85M
shares outstanding. The number of shares has increased by 501.05%
in one year.
| Shares Outstanding | 257.85M |
| Shares Change (YoY) | 501.05% |
| Shares Change (QoQ) | 500.14% |
| Owned by Institutions (%) | 8.11% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 95,678 |
| FTD / Avg. Volume | 4.75% |
Short Selling Information
The latest short interest is 4.45M, so 1.69% of the outstanding
shares have been sold short.
| Short Interest | 4.45M |
| Short % of Shares Out | 1.69% |
| Short % of Float | 2.04% |
| Short Ratio (days to cover) | 5.55 |
Valuation Ratios
The PE ratio is -1.92 and the forward
PE ratio is -1.96.
Adaptimmune Therapeutics's PEG ratio is
0.04.
| PE Ratio | -1.92 |
| Forward PE | -1.96 |
| PS Ratio | 0.76 |
| Forward PS | 0.3 |
| PB Ratio | 11.47 |
| P/FCF Ratio | -1.79 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Adaptimmune Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.92,
with a Debt / Equity ratio of 6.26.
| Current Ratio | 2.92 |
| Quick Ratio | 2.8 |
| Debt / Equity | 6.26 |
| Debt / EBITDA | -1.41 |
| Debt / FCF | -0.98 |
| Interest Coverage | -20.54 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $351,841.9 |
| Profits Per Employee | $-139,948.62 |
| Employee Count | 506 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | 3.58M |
| Effective Tax Rate | -5.32% |
Stock Price Statistics
The stock price has increased by -73.27% in the
last 52 weeks. The beta is 2.85, so Adaptimmune Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.85 |
| 52-Week Price Change | -73.27% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.65 |
| Relative Strength Index (RSI) | 47.22 |
| Average Volume (20 Days) | 2,015,091 |
Income Statement
In the last 12 months, Adaptimmune Therapeutics had revenue of 178.03M
and earned -70.81M
in profits. Earnings per share was -0.28.
| Revenue | 178.03M |
| Gross Profit | 177.96M |
| Operating Income | -68.76M |
| Net Income | -70.81M |
| EBITDA | -52.66M |
| EBIT | -63.89M |
| Earnings Per Share (EPS) | -0.28 |
Full Income StatementBalance Sheet
The company has 91.14M in cash and 74.21M in
debt, giving a net cash position of 16.93M.
| Cash & Cash Equivalents | 91.14M |
| Total Debt | 74.21M |
| Net Cash | 16.93M |
| Retained Earnings | -1.09B |
| Total Assets | 158.07M |
| Working Capital | 51.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -73.21M
and capital expenditures -2.72M, giving a free cash flow of -75.93M.
| Operating Cash Flow | -73.21M |
| Capital Expenditures | -2.72M |
| Free Cash Flow | -75.93M |
| FCF Per Share | -0.05 |
Full Cash Flow StatementMargins
Gross margin is 99.96%, with operating and profit margins of -38.62% and -39.78%.
| Gross Margin | 99.96% |
| Operating Margin | -38.62% |
| Pretax Margin | -37.77% |
| Profit Margin | -39.78% |
| EBITDA Margin | -29.58% |
| EBIT Margin | -38.62% |
| FCF Margin | -42.65% |
